Bristol's Belatacept Gets Wary Green Light From FDA Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The company proposed a REMS in advance for the kidney transplant drug, and post-market safety monitoring is indeed essential, committee members said.